Results 101 to 110 of about 73,182 (252)

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada   +13 more
wiley   +1 more source

Treg‐stromal cell axis in tissue repair and autoimmune diseases: Mechanisms and clinical translation

open access: yesRheumatology &Autoimmunity, EarlyView.
The Treg‐stromal cell axis as a central regulator of tissue repair and immune tolerance. Under physiological conditions, bidirectional communication between Tregs and stromal cells—mediated by cell‐surface molecular contacts, anti‐inflammatory cytokines, and extracellular vesicles—orchestrates inflammation resolution, immune tolerance, and complete ...
Peiyan Zhang   +2 more
wiley   +1 more source

PUB015 A Pooled Analysis of Efficacy and Safety of CTLA-4 Antigen in the Treatment of Cancer [PDF]

open access: yesJournal of Thoracic Oncology, 2017
X. Cui   +7 more
openaire   +1 more source

Intersection of systemic lupus erythematosus and autoimmune thyroid disease: Shared pathophysiology, epidemiology, diagnosis, and management

open access: yesRheumatology &Autoimmunity, EarlyView.
A proposed mechanistic framework of systemic lupus erythematosus (SLE) and autoimmune thyroid disease (AITD) pathogenesis. In Stage 1, genetically susceptible individuals harbor risk variants within major histocompatibility complex (HLA) and non‐HLA loci that impair central and peripheral immune tolerance mechanisms within the thymic and peripheral ...
Elisa Elisa   +3 more
wiley   +1 more source

Advances in research on layered double hydroxides for biomedical applications

open access: yesSmart Molecules, EarlyView.
Layered double hydroxides (LDHs) are pH‐responsive nanomaterials with broad biomedical applications. This review summarizes LDH synthesis methods and compares their advantages. It highlights LDHs' progress in cancer therapy, including chemo‐photothermal, chemo‐immunotherapy, and photodynamic‐immunotherapy combinations and their potential in bone repair.
Xinhui Yang   +13 more
wiley   +1 more source

Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti‐programmed cell death‐1 (anti‐PD‐1) agents are now the standard for platinum‐resistant recurrent/metastatic HNSCC.
Xiao‐Tong Yan   +2 more
wiley   +1 more source

Skin Abnormalities at Checkpoint Inhibitor Therapy Initiation Are Associated With Skin Rash Development in Oncology Patients

open access: yesAllergy, EarlyView.
Skin tape strip lipidomic analysis revealed preexisting skin barrier lipid abnormalities at day 0 that were further exacerbated after 6 weeks of CPI treatment. Significant changes in skin (but not plasma) proinflammatory cytokines were identified in future ircAE patients after 6 weeks of CPI immunotherapy.
Taras Lyubchenko   +9 more
wiley   +1 more source

A next-generation anti-CTLA-4 probody mitigates toxicity and enhances anti-tumor immunity in mice

open access: yesNature Communications
CTLA-4 is a promising target for immune checkpoint inhibition in cancer therapy, with CTLA-4 blockade achieving prolonged overall survival for responding patients. However, the progressively elevated doses of anti-CTLA-4 agents, aimed at achieving better
Weian Cao   +7 more
doaj   +1 more source

Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy

open access: yesAllergy, EarlyView.
In this Phase 2a trial, severely peanut‐allergic participants were randomized to abatacept versus placebo with peanut oral immunotherapy (OIT) for 24 weeks, followed by 12 weeks of OIT alone. No significant difference was observed for the primary efficacy outcome (the relative change from baseline in peanut‐specific/total IgE ratio at 24 weeks), but ...
Marie‐Lee Simard   +12 more
wiley   +1 more source

T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors

open access: yesAndrology, EarlyView.
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy